Tinea CapitisNCT07184203
Comparison Between Continuous and Pulse Itraconazole in Tinea Capitis in Children
A study testing Itraconazole (ITZ) in people with Tinea Capitis, run by Alexandria University at 1 site in Egypt.
Trial summary
A study to compare the efficacy of daily therapy versus pulse therapy of oral itraconazole in the treatment of tinea capitis in children based on clinical, mycological and dermoscopic evaluation. Read more about this study
- Who is it for?
- Ages 5 to 18 years
- Conditions the study is for
- Tinea Capitis
- What is being tested?
- Itraconazole (ITZ)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteEgypt
- Study dates
- 9 Mar 2025to 31 Dec 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Tinea capitis patients with ages ranging from 5 to 18 year
Who cannot join
- Patients with contraindications to itraconazole
- Patients with associated scalp disease.
- Patients weighing less than 20 Kg.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Comparative Clinicomycologic and Dermoscopic Study Between Daily and Pulse Therapy of Oral Itraconazole in Tinea Capitis in Children
A study to compare the efficacy of daily therapy versus pulse therapy of oral itraconazole in the treatment of tinea capitis in children based on clinical, mycological and dermoscopic evaluation.
- Conditions
- Tinea Capitis
- Being tested
- Itraconazole (ITZ)
- Medical subject headings
- Tinea Capitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Itraconazole (ITZ)Drug
therapy for tinea capitis orally
| Study group | Role | What they receive |
|---|---|---|
| Group A will receive itraconazole continuous daily regimen | Active comparator | Not described Receives: Drug: Itraconazole (ITZ) |
| Group B will receive itraconazole pulse regimen | Active comparator | Not described Receives: Drug: Itraconazole (ITZ) |
What is being measured
The primary outcome is the main question the study is designed to answer.
improvement of tinea capitis
cure of tinea capitis
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2025
- Study start9 Mar 2025
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tinea CapitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marina Aioub, Alexandria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07184203
- Sponsor's protocol ID
- 0108853
- Status last verified
- Feb 2025
- First submitted
- 14 Sep 2025
- Last updated
- 19 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Clinicomycologic and Dermoscopic Study Between Daily and Pulse Therapy of Oral Itraconazole in Tinea Capitis in Children
- ClinicalTrials.gov ID
- NCT07184203
- Acronym / sponsor ID
- 0108853
- Conditions
- Tinea Capitis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 9 Mar 2025 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 19 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study to compare the efficacy of daily therapy versus pulse therapy of oral itraconazole in the treatment of tinea capitis in children based on clinical, mycological and dermoscopic evaluation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A will receive itraconazole continuous daily regimen | Active comparator | Drug: Itraconazole (ITZ) |
| Group B will receive itraconazole pulse regimen | Active comparator | Drug: Itraconazole (ITZ) |
Who may qualify
- Ages
- 5 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Tinea capitis patients with ages ranging from 5 to 18 year
Key exclusion criteria (3 listed)
- Patients with contraindications to itraconazole
- Patients with associated scalp disease.
- Patients weighing less than 20 Kg.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Itraconazole (ITZ)therapy for tinea capitis orally | Drug | Group A will receive itraconazole continuous daily regimen, Group B will receive itraconazole pulse regimen |
Primary outcome
improvement of tinea capitis
Time frame: 3 months
cure of tinea capitis
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Tinea Capitis
Not yet recruitingObservational study
Clinical, Dermoscopic, and Mycological Characteristics of Tinea Capitis in Children
Fungal Infection by Site, Tinea Capitis
RecruitingObservational study
Population Pharmacokinetics of Terbinafine in Children With Tinea Capitis
Tinea Capitis
Active, not recruitingPhase 2/3
Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution Working
Tinea Capitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Itraconazole (ITZ) in people with Tinea Capitis, run by Alexandria University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marina K Aioub (00201223805043, marinaaioub10@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
improvement of tinea capitis (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Sep 2025; AzTrials last refreshed its copy on 30 Oct 2026.